Former CEO and Founder, Esther Alegria, Remains on Executive Team Focused on Driving Research & Development Through External Collaborations
Read MoreNews
APIE Therapeutics Welcomes Jim Greenwood to
Cary, NC — APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim...
Read MoreAPIE Therapeutics Provides Evidence that Activating
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
Read MoreAPIE Therapeutics Presented Preclinical Findings Supporting
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
Read MoreAPIE Therapeutics Prepares to Advance Pipeline
APIE Therapeutics appoints Robert Willette, Ph.D. to the newly created role of chief scientific officer.
Read MoreRTI International Licenses Portfolio of Compounds
The agreement advances APIE Therapeutics’ pursuit of a treatment for idiopathic pulmonary fibrosis, a rare lung disease
Read MoreEvents
ATS 2023 Respiratory Innovation Summit
May 19, 2023
During the ATS 2023 Respiratory Innovation Summit, APIE Therapeutics presented a poster demonstrating preclinical efficacy…
IPF Summit 2022
August 29, 2022
During the IPF Summit, APIE Therapeutics presented a poster describing the novel apelin receptor agonist…
International Workshop of Scleroderma Research
August 2, 2022
Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases…
APIE Therapeutics chosen as Start-Up Stadium Finalist
June 15, 2022
Start-Up Stadium was designed to provide start-up companies with the opportunity to access key members…
